Biofrontera's Ameluz Shows Promise in Acne Treatment, Eyes FDA Path
Event summary
- Phase 2b trial shows Ameluz® PDT reduced inflammatory acne lesions by 57.97% with 3-hour incubation vs. 36.51% with vehicle.
- 3-hour incubation regimen identified as optimal for further development in moderate to severe acne vulgaris.
- Company plans to present data to FDA in Q3 2026 to discuss next steps for acne indication.
- High patient satisfaction reported, with 85.7% of Ameluz® patients willing to repeat treatment.
The big picture
Biofrontera's positive Phase 2b results position Ameluz® as a potential new treatment for moderate to severe acne, a condition affecting millions in the U.S. The company is expanding beyond its current focus on actinic keratosis, tapping into a larger market with significant unmet needs. The shift could diversify its revenue streams but requires navigating a complex regulatory landscape. Success would strengthen its position in dermatology, particularly in physician-administered therapies.
What we're watching
- Regulatory Pathway
- Whether FDA will require additional trials before approving Ameluz® for acne vulgaris.
- Market Expansion
- How quickly Biofrontera can pivot from actinic keratosis to acne treatment in its commercial strategy.
- Competitive Positioning
- The pace at which competitors develop alternative PDT treatments for acne.
Related topics